bn 50726 has been researched along with cyclosporine in 1 studies
| Studies (bn 50726) | Trials (bn 50726) | Recent Studies (post-2010) (bn 50726) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
|---|---|---|---|---|---|
| 10 | 0 | 0 | 30,547 | 3,802 | 6,558 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braquet, P; Claude, JR; Dutertre-Catella, H; Martin, C; Massicot, F; Warnet, JM | 1 |
1 other study(ies) available for bn 50726 and cyclosporine
| Article | Year |
|---|---|
Protection against cyclosporin-induced nephrotoxicity: 1. Effect of a PAF antagonist, BN50726.
Topics: Animals; Azepines; Creatinine; Cyclosporine; Drug Interactions; Glutathione; Kidney Cortex; Kidney Diseases; Male; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Thienopyridines; Urea | 1994 |